Cancer bone metastasis was a common clinical phenotype, especially occurred in categories of breast,
prostate and lung cancer (general incidence >30%). Early diagnosis may improve human survival and,
drug treatment quality. To create paradigms of clinical treatment, overall study of blood biomarkers is
indispensable. This editorial discusses bone metastasis diagnosis by detecting cancer biomarkers.
Keywords: Bone Cancer; Neoplasm Metastasis; Drug Treatment; Tumor Models; Experiment Study
Cancer is the secondary leading cause of human mortality worldwide
[1,2]. Cancer bone metastasis is one of frequent cancer locations
for metastasis colony, especially for categories of breast, prostate
and lung cancer (general incidence >30%) [3-7]. Early diagnosis may
improve human survival and, drug treatment quality. To create paradigms
of clinical treatment, overall study of blood biomarkers is indispensable.
There are a lot of different anticancer drugs in the clinic. How to
evaluate drug responses and clinical drug selection plays key roles.
Drug sensitivity testing is widely used for drug selection in the clinic
[8-14]; However, different types of personalized medicine strategies
are also very important for clinical trials [8-19].
Drug targets and responses to bone metastasis have different
types, categories and systems [20-23]. At present, several types of
drug treatment have been promising, such as herbal medicine [24-
26], personalized medicine (PM) [9-19], drug combination [27-28]
and pharmaceutical innovation [29]. These kinds of therapeutic study
can be very useful for drug selection in the clinic. Cancer bone metastatic
study is important to improve in diagnosis and therapeutic
selection. More mimic experimental tumor models to clinical situations
should be built in present experimental study. Blood biomarker
detection can help these disciplines. By update experimental models,
clinical success may be reached.
PM can promote clinical drug treatment. How to implement them
is a modern challenge [15,19]. However, it is difficult to use conventional
PM for bone metastasis. Bone metastasis is difficult to observe
in the clinic. New pathways should be explored to enrich targets and
mechanisms in circulating tumors and biomarkers [30]. Knowledge
should be accumulation for biomarker medical significance in the
clinic. Many new discoveries could be expected from these preclinical
evaluations and clinical diagnosis.
Lu DY (2014) Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics. Woodhead Publishing, Elsevier, UK (ISBN. 978-0-08-100346-6).
ISSN: 2574 -1241
Abstract
PDF
